Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 6/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29083228 | 1.00 | EPHX1 (0.45) | EPHX1HPGDRECQLMAPTKDM4E | |
| SCHEMBL21649154 | 0.86 | EPHX1 (0.46) | EPHX1HPGDRECQLMAPTKDM4E | |
| SCHEMBL31734338 | 0.86 | EPHX1 (0.46) | EPHX1HPGDRECQLMAPTKDM4E | |
| SCHEMBL25185104 | 0.85 | NR1H2 (0.40) | EPHX1HPGDEPHX2USP2SMN1; SMN2 | |
| SCHEMBL17125681 | 0.84 | EPHX1 (0.49) | EPHX1HPGDRECQLMAPTKDM4E | |
| SCHEMBL4172346 | 0.84 | EPHX1 (0.49) | EPHX1HPGDRECQLMAPTKDM4E | |
| SCHEMBL21411217 | 0.84 | EPHX1 (0.41) | EPHX1HPGDRECQLMAPTKDM4E | |
| SCHEMBL15416696 | 0.84 | EPHX1 (0.41) | EPHX1HPGDRECQLMAPTKDM4E | |
| SCHEMBL17630680 | 0.81 | HPGD (0.47) | EPHX1HPGDRECQLMAPTKDM4E | |
| SCHEMBL1965038 | 0.81 | HPGD (0.47) | EPHX1HPGDRECQLMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4674484-A2 | THIENOPYRROLE COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-4291562-B1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20240342292-A1 | Compounds for the Degradation of EGFR Kinase | BEIGENE SWITZERLAND GMBH (CH) | 2024-10-17 | — | — | US | disclosed |
| US-20240217990-A1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES, INC. | 2024-07-04 | — | — | US | disclosed |
| EP-4291562-A1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-12-20 | — | — | EP | disclosed |
| CN-116783202-A | Thienopyrrole compounds | 吉利德科学公司 | 2023-09-19 | — | — | CN | disclosed |
| WO-2023098656-A1 | COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE | BEIGENE, LTD. (GB) | 2023-06-08 | — | — | WO | disclosed |
| WO-2022173722-A1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217990-A1 | THIENOPYRROLE COMPOUNDS | SSB, TPMT, LCP2 | EPHX1 2462/4885HPGD 328/4885RECQL 765/4885 |
| US-20240342292-A1 | Compounds for the Degradation of EGFR Kinase | EGFR, ERBB2, ERBB3 | EPHX1 2777/4885HPGD 4192/4885RECQL 3760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.